References
- Belderbos JS, Heemsbergen WD, De Jaeger K, et al (2006). Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 66, 126-34. https://doi.org/10.1016/j.ijrobp.2006.04.034
- Blackstock AW, Ho C, Butler J, et al (2006). Phase Ia/Ib chemoradiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol, 1, 434-40. https://doi.org/10.1097/01243894-200606000-00010
- Bradley J, Graham MV, Winter K, et al (2005). Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys, 61, 318-28. https://doi.org/10.1016/j.ijrobp.2004.06.260
- Britton KR, Starkschall G, Tucker SL, et al (2007). Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys, 68, 1036-46. https://doi.org/10.1016/j.ijrobp.2007.01.021
- Curran WJ, Scott CB, Langer CJ, et al (2003). Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410. Proc Am Soc Clin Oncol, 22, 621a (abstract 2499).
- Eschmann SM, Friedel G, Paulsen F, et al (2007). Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage lll non-small cell lung cancer. Lung cancer, 55, 165-71. https://doi.org/10.1016/j.lungcan.2006.09.028
- Fox J, Ford E, Redmond K, et al (2009). Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 74, 341-8. https://doi.org/10.1016/j.ijrobp.2008.07.063
- Gillham C, Zips D, Pönisch F, et al (2008). Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol, 88, 335-41. https://doi.org/10.1016/j.radonc.2008.05.004
- Gilman MD, Aquino SL (2005). State-of-the-art FDG-PET imaging of lung cancer. Semin Roentgenol, 40, 143-53. https://doi.org/10.1053/j.ro.2005.01.008
- Guckenberger M, Wilbert J, Richter A, et al (2011). Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys, 79, 901-8. https://doi.org/10.1016/j.ijrobp.2010.04.050
- Hong R, Halama J, Bova D, et al (2007). Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys, 67, 720-6. https://doi.org/10.1016/j.ijrobp.2006.09.039
- Kim TH, Cho KH, Pyo HR, et al (2005). Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 62, 995-1002. https://doi.org/10.1016/j.ijrobp.2004.12.025
- Kim TY, Yang SH, Lee SH, et al (2002). A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol, 25, 238-43. https://doi.org/10.1097/00000421-200206000-00007
- Kim YS, Yoon SM, Choi EK, et al (2005). Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys, 62, 76-81. https://doi.org/10.1016/j.ijrobp.2004.09.038
- Kong FM, Ten Haken RK, Schipper MJ, et al (2005). High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys, 63, 324-33. https://doi.org/10.1016/j.ijrobp.2005.02.010
- Kupelian PA, Ramsey C, Meeks SL, et al (2005). Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys, 63, 1024-8. https://doi.org/10.1016/j.ijrobp.2005.04.046
- Li BS, Gong HY, Huang W, et al (2011). Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer. Am J Clin Oncol [Epub ahead of print].
- MacManus M, Nestle U, Rosenzweig KE, et al (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol, 91, 85-94. https://doi.org/10.1016/j.radonc.2008.11.008
- Nestle U, Kremp S, Grosu AL (2006). Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol, 81, 209-25. https://doi.org/10.1016/j.radonc.2006.09.011
- Nestle U, Walter K, Schmidt S, et al (1999). 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys, 44, 593-7. https://doi.org/10.1016/S0360-3016(99)00061-9
- Rengan R, Rosenzweig KE, Venkatraman E, et al (2004). Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 60, 741-7. https://doi.org/10.1016/j.ijrobp.2004.04.013
- Seppenwoolde Y, Muller SH, Theuws JC, et al (2000). Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 47, 681-90. https://doi.org/10.1016/S0360-3016(00)00454-5
- van Baardwijk A, Bosmans G, Boersma L, et al (2007). PETCT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys, 68, 771-8. https://doi.org/10.1016/j.ijrobp.2006.12.067
- Willner J, Baier K, Caragiani E, et al (2002). Dose, volume, and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 52, 382-9. https://doi.org/10.1016/S0360-3016(01)01823-5
- Woodford C, Yartsev S, Dar AR, et al (2007). Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys, 69, 1316-22. https://doi.org/10.1016/j.ijrobp.2007.07.2369
Cited by
- Staging with PET-CT in Patients with Locally Advanced Non Small Cell Lung Cancer is Superior to Conventional Staging Methods in Terms of Survival vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3743
- Clinical Outcome of Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: The Kyung Hee University Medical Center Experience vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1545
- Potential Impact of Atelectasis and Primary Tumor Glycolysis on F-18 FDG PET/CT on Survival in Lung Cancer Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4085
- Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10171
- Feasibility of Image-Guided Radiotherapy and Concurrent Chemotherapy for Locally Advanced Nonsmall Cell Lung Cancer vol.33, pp.3, 2015, https://doi.org/10.3109/07357907.2014.1001896
- Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer vol.12, pp.1, 2017, https://doi.org/10.1371/journal.pone.0170901
- Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review vol.44, pp.11, 2017, https://doi.org/10.1007/s00259-017-3762-9